

SEQUENT SCIENTIFIC LIMITED
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2012

(₹ in Lakhs)

S.No.	Particulars	STANDALONE			
		Quarter Ended			Year Ended
		30-Jun-12 UNAUDITED	31-Mar-12 UNAUDITED	30-Jun-11 UNAUDITED	31-Mar-12 AUDITED
Part-I					
1	Income from operations				
a	Net Sales / Income from Operations (net of excise duty)	7,166.20	9,915.10	6,861.50	33,188.00
b	Other Operating Income	14.90	55.20	-	55.20
	Total income from operations (net)	7,181.10	9,970.30	6,861.50	33,243.20
2	Expenses				
a	Cost of materials consumed	3,289.10	4,818.58	3,549.40	18,074.80
b	Purchase of stock-in-trade	157.90	253.92	157.70	851.30
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	441.80	434.20	210.90	61.20
d	Employee benefits expenses	607.80	642.90	632.30	2,543.70
e	Depreciation and amortisation expenses	561.60	529.00	442.80	2,102.80
f	Other expenses	3,096.90	1,644.17	1,621.36	8,165.00
	Total expenses	8,155.10	8,322.77	6,614.46	31,798.80
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	(974.00)	1,647.53	247.04	1,444.40
4	Other Income	86.40	314.30	613.40	1,132.70
5	Profit/(Loss) from ordinary activities before finance cost and exceptional items (3±4)	(887.60)	1,961.83	860.44	2,577.10
6	Finance cost	736.30	791.03	665.40	2,826.50
7	Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5±6)	(1,623.90)	1,170.80	195.04	(249.40)
8	Exceptional items	-	-	-	-
9	Profit/(Loss) from ordinary activities before tax (7±8)	(1,623.90)	1,170.80	195.04	(249.40)
10	Tax Expense	(105.90)	(262.90)	145.10	(396.40)
11	Net Profit/(Loss) from Ordinary activities after tax (9±10)	(1,518.00)	1,433.70	49.94	147.00
12	Extraordinary items	-	-	-	-
13	Net Profit/(Loss) for the period(11±12)	(1,518.00)	1,433.70	49.94	147.00
14	Paid-up equity share capital (Face Value per share Rs.10 each)	2,193.50	2,193.50	2,193.50	2,193.50
15	Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year				10,537.20
16.i	Earnings Per Share before Extraordinary Items for the period (Non-Annualised)				
	Basic (Rs.)	(6.92)	6.54	0.23	0.67
	Diluted (Rs.)	(6.92)	6.54	0.23	0.67
16.ii	Earnings Per Share after Extraordinary Items for the period (Non-Annualised)				
	Basic (Rs.)	(6.92)	6.54	0.23	0.67
	Diluted (Rs.)	(6.92)	6.54	0.23	0.67
Part-II					
A	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	No. of Shares	9,692,781	9,745,212	6,028,969	9,745,212
	% of Share Holding	44.19%	44.43%	27.49%	44.43%
2	Promoters and Promoter Group Shareholding				
a)	Pledged / Encumbered				
1.	No. of shares	1,000,000	1,000,000	2,300,000	1,000,000
2.	Percentage of shares (as a % of the total shareholding of promoter & promoter group)	8.17%	8.20%	14.46%	8.20%
3.	Percentage of shares (as a % of the total share capital of the company)	4.56%	4.56%	10.49%	4.56%
b)	Non-encumbered				
1.	No. of shares	11,242,410	11,189,979	13,606,222	11,189,979
2.	Percentage of shares(as a % of the total shareholding of promoter & promoter group)	91.83%	91.80%	85.54%	91.80%
3.	Percentage of shares (as a % of the total share capital of the company)	51.25%	51.01%	62.02%	51.01%
B	INVESTOR COMPLAINTS			Quarter ended 30 Jun 2012	
	Pending at the beginning of the quarter			Nil	
	Received during the quarter			Nil	
	Disposed of during the quarter			Nil	
	Remaining unresolved at the end of the quarter			Nil	

Notes:

- The unaudited financial results were taken on record by the Board of Directors at its meeting held on August 14, 2012.
- The Statutory Auditors have performed a limited review of the standalone financial results for the quarter ended as on June 30, 2012 of the Company as required by Clause 41 of the Listing Agreement.
- Segment Results

The company has identified Pharmaceuticals and Specialty Chemicals as its business segments, Segments have been identified taking in to account the nature of products, the differing risks & returns, the organisational structure & the internal reporting system.

Sl. No	Particulars	Quarter Ended			Year Ended
		30-Jun-12 UNAUDITED	31-Mar-12 UNAUDITED	30-Jun-11 UNAUDITED	31-Mar-12 AUDITED
1	Segment Revenue				
	a) Pharmaceuticals	6,247.83	8,329.39	5,867.60	28,213.31
	b) Specialty Chemicals	933.27	1,640.91	993.90	5,029.89
	Net Sales /Income from Operations	7,181.10	9,970.30	6,861.50	33,243.20
2	Segment Results				
	Profit or Loss before Tax and Interest from Each Segment				
	a) Pharmaceuticals	(684.49)	1,275.67	334.10	1,109.73
	b) Specialty Chemicals	(108.44)	453.89	250.80	1,085.62
	Total	(792.93)	1,729.56	584.90	2,195.35
	Less (i) Finance Cost	736.30	725.13	697.60	2,826.50
	(ii) other unallocable expenditure net off unallocable income	94.67	(166.37)	(307.74)	(381.75)
	Total Profit Before Tax	(1,623.90)	1,170.80	195.04	(249.40)
3	Capital Employed				
	a) Pharmaceuticals	32,519.95	26,895.91	44,867.70	26,895.91
	b) Specialty Chemicals	1,107.35	2,844.96	2,224.50	2,844.96
	c) Unallocated	(14,533.10)	(10,843.17)	(14,012.70)	(10,843.17)
	Total	19,094.20	18,897.70	33,079.50	18,897.70

- Figures for the quarter ended 31 March 2012 are the balancing figures between audited figures and the published year-to-date figures up to the third quarter of the previous financial year.
- Figures for previous periods have been regrouped and rearranged, wherever necessary, to confirm to the relevant current period classification.

For Sequent Scientific Limited

Place: Bangalore

Date : August 14, 2012

K.R.Ravishankar
Chairman & Managing Director